Table 1 Characteristics of children with PRD treated with adalimumab ≥ 12 weeks with or without methotrexate

General information study cohort

 Female sex, n (%)

15 (53.6)

10 (71.4)

5 (35.7)

0.13

 Median age at diagnosis, years [IQR]

7.1 [4.4, 10.1]

6.3 [2.4, 9.00]

8.8 [5.7, 10.1]

0.19

 Median age at first visit, years [IQR]

11.3 [8.9, 13.2]

11.3 [8.9, 13.5]

11.5 [9.3, 12.8]

0.82

 Median body weight, kg [IQR]

38.7 [31.9, 54.1]

35.7 [31.7, 52.7]

43.7 [33.0, 54.9]

0.59

 Comorbidities, n (%)

3 (10.7)

0

3 (21.4%)^a

0.22

Diagnosis, n (%)

 JIA

20 (71.4)

12 (85.7)

8 (57.1)

0.21

 Idiopathic Uveitis

7 (25.0)

2 (14.3)

5 (35.7)

 CRMO

1 (3.6)

0

1 (7.1)

Disease activity

 Median CRP, mg/L [IQR] (ref < 10)

Missing, n (%)

0.3 [0.1, 1.1]

1 (3.6)

0.1 [0.1, 0.3]

0.6 [0.3, 1.3]

1 (7.1)

0.01

 Median ESR, mm/h [IQR] (ref < 15)

Missing, n (%)

5.5 [4.0, 6.3]

4 (14.3)

6.0 [5.0, 7.0]

1 (7.1)

4.00 [4.0, 6.0]

3 (21.4)

0.28

 Median PGA, cm [IQR]

0 [0, 1.0]

0.50 [0, 1.8]

0 [0, 1.0]

0.53

 Median PPGA, cm [IQR]

0 [0, 1.0]

1.00 [0, 1.8]

0 [0, 0]

0.05

Adalimumab treatment

 Median time since start, months [IQR]

17.6 [8.4, 25.1]

17.8 [9.6, 21.6]

15.8 [8.5, 30.8]

0.78

 Absolute median dose, mg [IQR]

40.0 [28.8, 40.0]

40.0 [25.0, 40.0]

40.0 [30.0, 40.0]

0.77

 Median dose per BSA, mg/m² [IQR]

25.3 [22.9, 28.3]

25.1 [21.3, 32.0]

25.4 [23.6, 27.2]

0.93

 Median frequency, days [IQR]

14.0 [14.0, 14.0]

14.0 [14.0, 14.0]

14.0 [14.0, 14.0]

0.35

Methotrexate treatment

 Median time since start, months [IQR]

n.a

23.4 [19.7, 59.2]

n.a

n.a

 Absolute median dose, mg [IQR]

11.0 [10.0, 15.0]

 Median dose per BSA, mg/m² [IQR]

9.0 [6.6, 9.8]

 Median frequency, days [IQR]

7.0 [7.0, 7.0]

Concomitant treatment at inclusion, n (%)

 Corticosteroids, systemic^b

2 (7.1)^b

2 (14.3)^b

0

0.09

 NSAIDs, on demand

4 (14.3)

2 (14.3)

2 (14.3)

 NSAIDs, fix administration

3 (10.7)

1 (7.1)

2 (14.3)

 Ocular steroids^b

4 (14.3)

4 (28.6)

0